haloperidol and allopurinol

haloperidol has been researched along with allopurinol in 23 studies

Research

Studies (23)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (4.35)	18.7374
1990's	0 (0.00)	18.2507
2000's	13 (56.52)	29.6817
2010's	9 (39.13)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andrews, PR; Craik, DJ; Martin, JL	1
Topliss, JG; Yoshida, F	1
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA	1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY	2
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J	1
Lombardo, F; Obach, RS; Waters, NJ	1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Glen, RC; Lowe, R; Mitchell, JB	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y	1
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL	1
Akhondzadeh, S; Amini, H; Safarcherati, A	1
Akhondzadeh, S; Amini, H; Milajerdi, MR; Tehrani-Doost, M	1
Janicijevic-Hudomal, S; Kaurinovic, B; Popovic, M; Rasic, J; Trivic, S	1
Chen, Y; Gao, F; Huang, Z; Li, W; Liao, H; Lu, S; Shi, G; Sun, T; Wang, B; Xu, H; Zhang, Y; Zheng, F; Zhong, S	1

Reviews

1 review(s) available for haloperidol and allopurinol

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for haloperidol and allopurinol

Article	Year
Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Progress in neuro-psychopharmacology & biological psychiatry, 2005, Volume: 29, Issue:2 Topics: Adult; Allopurinol; Antipsychotic Agents; Case-Control Studies; Dopamine Antagonists; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Time Factors; Treatment Outcome	2005
Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar disorders, 2006, Volume: 8, Issue:5 Pt 1 Topics: Acute Disease; Adult; Allopurinol; Antimanic Agents; Basal Ganglia Diseases; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Lithium Compounds; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome	2006

Article

Year

Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.

Progress in neuro-psychopharmacology & biological psychiatry, 2005, Volume: 29, Issue:2

Topics: Adult; Allopurinol; Antipsychotic Agents; Case-Control Studies; Dopamine Antagonists; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Time Factors; Treatment Outcome

2005

Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial.

Bipolar disorders, 2006, Volume: 8, Issue:5 Pt 1

Topics: Acute Disease; Adult; Allopurinol; Antimanic Agents; Basal Ganglia Diseases; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Lithium Compounds; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome

2006

Other Studies

20 other study(ies) available for haloperidol and allopurinol

Article	Year
Functional group contributions to drug-receptor interactions. Journal of medicinal chemistry, 1984, Volume: 27, Issue:12 Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship	1984
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. Journal of medicinal chemistry, 2001, Jul-19, Volume: 44, Issue:15 Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water	2001
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. Journal of medicinal chemistry, 2002, Jun-20, Volume: 45, Issue:13 Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding	2002
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5 Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution	2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19 Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Predicting phospholipidosis using machine learning. Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5 Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16 Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone	2016
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. PloS one, 2016, Volume: 11, Issue:10 Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat	2016
Effects of various drugs on alcohol-induced oxidative stress in the liver. Molecules (Basel, Switzerland), 2008, Sep-23, Volume: 13, Issue:9 Topics: Alanine Transaminase; Animals; Azithromycin; Bromocriptine; Catalase; Ethanol; Glutathione; Glutathione Reductase; Haloperidol; Lipid Peroxidation; Liver; Male; Oxidative Stress; Peroxidase; Rats; Rats, Wistar; Xanthine Oxidase	2008
Effect of N-n-butyl haloperidol iodide on ROS/JNK/Egr-1 signaling in H9c2 cells after hypoxia/reoxygenation. Scientific reports, 2015, Jul-02, Volume: 5 Topics: Acetylcysteine; Antipyrine; Cell Hypoxia; Cell Line; Early Growth Response Protein 1; Edaravone; Gene Expression Regulation; Haloperidol; Humans; MAP Kinase Kinase 4; MAP Kinase Signaling System; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxidative Stress; Reactive Oxygen Species; Xanthine Oxidase	2015